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Introduction: Over the past ten years, a large number of New Psychoactive Substances (NPS) have 
entered the recreational drug scenario. NPS intake has been associated with health-related risks, and 
especially so for vulnerable populations such as the youngsters. Currently, most knowledge on the 
NPS health effects is learnt from both a range of users' reports, made available through the 
psychonauts’ web fora, and from the few published, related toxicity, clinical observations. 
Areas covered: This paper aims at providing an overview of NPS effects on youngsters’ mental 
health, performing a systematic review of the current related knowledge.   
Expert opinion: NPS consumption poses serious health risks, due to both a range of unpredictable 
clinical pharmacological properties and the typical concomitant use of other psychoactive 
molecules, which can lead to near misses and fatalities. In comparison with adults, the central 
nervous system of children/adolescents may be more vulnerable to the activity of these molecules, 
hence raising even further the levels of health-related concerns. Further research is needed, to 








Over the last decade, the emergence of a range of New Psychoactive Substances (NPS) has progres-
sively changed the landscape [1] of the drug market, which has shifted with the raising use of the 
Web from a ‘street’ to a ‘virtual’/online one [2-3]. NPS include synthetic cannabinoids, cathinone 
derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine deriva-
tives, phencyclidine-like dissociatives, piperazines, Gamma-AminoButyric Acid (GABA) -A/B re-
ceptor agonists, a range of prescribed medications (e.g. benzodiazepine derivatives; methylpheni-
date look-alikes; and fentanyl analogues), psychoactive plants/herbs, and a large series of perfor-
mance and image enhancing drugs [1]. Since the United Nations Office on Drugs and Crime 
(UNODC) monitoring in 2009, NPS have been emerging every year at an average rate of about one 
substance per week [4-6]. Worldwide, synthetic cannabinoids and synthetic cathinones represent the 
largest groups of NPS being monitored [4; 7-8]. Overall, users are typically attracted by NPS due to 
curiosity and diffusion of social media users’ experiences; easy availability/affordability from 
online drug shops; legality; intense psychoactive effects and likely lack of detection in routine drug 
screenings [6, 9-10]. Interestingly, drivers for NPS use among students from a University in North-
ern Ethiopia appeared to be not only the easy access to NPS and prior experiences with substances, 
but also interpersonal factors, including detachment from family and difficulties in socialization; 
environmental factors such as limited recreational alternatives; and a  low academic performance 
[11]. 
Due to the rapid life cycle of these substances, current health professionals’ NPS technical under-
standing is a reason of concern. Recruiting 3,551 young people and health professionals to ask 
about their NPS knowledge, the European-wide RedNet Project found that the 69% of health pro-
fessionals possessed levels of “very good/good” access to NPS information, although for some 16% 
of them considered their knowledge “basic/essential” or even “insufficient” [10; 12-14]. Investigat-
ing the experiences and attitudes of adolescents/young adults towards NPS in a sample of over 
12,000 young people (aged 15-24 years) across the 27 European Union (EU) Member States, a var-
iable rate of NPS intake, ranging from 16% in Ireland to 0.8-1.6% in Italy, Finland and Greece has 
been identified [15]. Most NPS users appeared to be young (aged 15-24), males, and from urban ar-
eas [16-19]. In the UK, 2.6% of young people (aged 16-24) reported having used NPS in the last 
year [16]. Conversely, there are suggestions of a recently (from 2009 to 2013) increase in NPS use 
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among both European and American young users [17-18]. With the help of both an online survey 
and a telephone interview, a UK-based specialist drug charity recently assessed the levels of NPS 
use in some 1,604-young people aged under 25, finding a lifetime prevalence of NPS use around 
66%, being synthetic cannabinoids the most commonly reported NPS [20-22]. Prior to ingesting an 
NPS, most youngsters had researched on these molecules checking on both YouTube®, pro-drug 
websites and user-driven educational/harm-reduction fora such as Erowid or Bluelight, which both 
provide advice on dosage, typical psychoactive effects, and best possible drug combinations [14]. 
Even though perceived as safer compared with traditional drugs of abuse, NPS intake, co-occurring 
substance use and mental health diseases have been associated with adverse consequences, includ-
ing risk of death, suicide/self-harm, homelessness, offending, poor physical health and social prob-
lems [23-24], with intake NPS being particularly detrimental in psychiatric clients [25-32].  
 
1.1 NPS and the youngsters; prevalence issues 
Some London area, questionnaire-based, school surveys, carried out in subjects aged 15-18 years-
old identified prevalence rates of NPS use ranging from 1.1 to 8% [33-34]. Conversely, an Australi-
an questionnaire-based survey recruiting 682 subjects aged 18-35 years-old identified a relatively 
high (17.6%) lifetime use of NPS, mostly synthetic cannabinoids [35]. Interestingly, the prevalence 
of NPS (mainly synthetic cannabinoids) but also of cannabis and cocaine intake was significantly 
higher in a psychiatric sample of Italian young adults (aged 18-26 years-old) compared with a 
healthy population, where alcohol misuse and binge drinking behaviour were more prevalent [36]. 
Moreover, NPS availability and knowledge seemed to be significantly higher among healthy Italian 
young adults from urban areas and mostly related to mephedrone (26%) [37]. Finally, the actual 
NPS intake was strongly related with binge drinking and reported by 4.7% of the sample, with 
mephedrone, synthetic cannabinoids and Salvia divinorum being the most popular NPS [37]. 
 
1.2 Epidemiology of NPS use in young clubbers’ sub-populations 
A pilot-study aimed at describing drug, including NPS, intake levels in a population of young adults 
(18-30 years-old; n=273 subjects) attending 5 nightclubs in Rome through a self-reported question-
naire, identifying a lifetime recreational drugs, including NPS, use in the 78% of the sample, being 
the most popular molecules identified amyl nitrite (45%), synthetic cannabinoids (35%), lysergic 
acid diethylamide (LSD) (24%), mephedrone (18.8%), ketamine (18%), gamma-hydroxybutyrate 
(GHB) (10.2%), psilocybin (4%), and Salvia divinorum (3.2%) [38]. A survey-based study evaluat-
ing 682 adults (aged 18-25 years) entering electronic dance music events in New York City report-
ed a lifetime use of any NPS in 35.1% of participants [39]. Synthetic cannabinoids were the most 
prevalent NPS reported (16.3%), followed by psychedelic phenethylamines (14.7%), synthetic cath-
inones (6.9%), other psychedelics (6.6%), tryptamines (5.1%) and dissociatives (4.3%) [38]. Simi-
larly, apart from the methylenedioxymethamphetamine (MDMA), butylone and methylone, both in-
cluded among phenethylamines, were respectively identified in 47.9% and 10.4% of hair samples 
from 679 nightclub/festival-attending young subjects (aged 18-25) in New York City [40]. A sur-
vey-based study recruiting 679 American young adults (aged 18-25) entering electronic dance mu-
sic parties evaluated ecstasy/MDMA vs non-ecstasy users and concomitant NPS use [41]. Ecstasy 
users were more likely to report use of NPS (e.g. psychedelic phenethylamines and synthetic cathi-
nones) and/or remaining unknown drugs (powders or liquids) compared to non-ecstasy users [42]. 
To profile mephedrone and synthetic cannabinoids’ users, a US questionnaire-based survey carried 
out by Kelly et al. [43] recruited 18-40 years-old adults (n=1,740) attending a range of night club 
venues in New York City. Latinos and younger adults seemed to be more likely to use synthetic 
cannabinoids, although the use of a variety of other substances, including alcohol, energy drink, 
club, and prescription drugs resulted to be quite prevalent [43]. 
 
1.3 NPS use amongst youngsters; web-based surveys/studies 
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An online survey recruiting a sample aged 13 to 30-years-old (www.thestudentroom.co.uk) identi-
fied large levels of lifetime prevalence (31%) of NPS use, with mephedrone (41%), Salvia 
divinorum (20%) and synthetic cannabinoids (11%) having been the most commonly reported NPS 
[12]. Finally, a non-participant netnographic qualitative study, collecting data from a list of cyber-
drug/psychonauts’ communities, reported that NPS use was mainly carried out by adolescents and 
young adults (aged 15-35 years) [13].  
 
In the NPS acute/medium/long-term toxicity effects’ related literature, there is a severe lack of pre-
clinical studies, animal testing data, and clinical trials. Conversely, typical sources of information 
include the web fora psychonauts’ self-reports; the self-reported surveys focusing on sub-
populations of NPS users [44]; the case reports/series’ anecdotal descriptions; and, finally, the lim-
ited number of poison information services and emergency departments (ED) reports [45]. The rap-
id rate with which NPS appear, together with the uncertainties over their actual ‘branding’ and 
composition, pose substantial challenges for mental health care providers [1; 46], and especially so 
for child and adolescent mental health workers [7; 13-14; 47-48]. 
 
1.4 NPS-related fatalities in youngsters 
In a UK-based study, the number of fatalities linked to NPS has risen in recent years from 10 in 
2009 to at least 67 deaths in 2015 [49]. Recent research focussed on UK mephedrone fatalities in a 
sample of individuals aged 16-24 years at the time of death. Some 30 cases (with a mean age of 20 
years-old), mostly presenting with a history of drug use (85%), were identified [50]. Furthermore, 
all (n=12) fatalities directly or indirectly related to misusing drugs registered in Ibiza from January 
to September 2015 were analysed. Most (9 out of 12) cases were males, with a mean age of 30.5 
years, and two victims of 18 years-old were reported as well [51].  
 
1.5 Aims 
Given the need and relevance of obtaining information and data concerning the role of NPS in men-
tal health, and particularly amongst the vulnerable group of youngsters, a systematic review was 
here performed. We aimed here at better understanding how the different NPS may influ-
ence/determine a range of mental health consequences. 
 
2. Materials and Methods 
A systematic electronic search including original papers up to August 2019 was carried out by using 
the Pubmed/Medline database. The information was gathered in accordance with PRISMA 
guidelines (http://www.prisma-statement.org/PRISMAStatement/Default.aspx.). LO and SC 
combined the search strategy of free text terms and exploded a range of MESH headings relating to 
the topics of youngsters’ mental health and New/novel Psychoactive Substances. The search terms 
“new psychoactive substances” and “NPS” were cross-referenced with the terms “Mental Health 
disorders”, “Youngsters”, “Adolescence”, “Young”; and major categories of mental illnesses, such 
as “Anxiety Disorders”, “Mood Disorders”, “Bipolar Disorder”, “Depressive disorder”, 
“Schizophrenia”, “Psychotic Disorders”, “Dementia”, “Cognitive disorders”, “Eating Disorders”, 
“Sleep disorders” and “Attention-Deficit Hyperactivity Disorder”. Thus, in order to retrieve the 
articles that were most relevant to our research question the following search string was applied: 
((New psychoactive substances[Title/Abstract]) OR (Novel psychoactive 
substances[Title/Abstract])) OR (NPS [Title/Abstract]) AND (Mental Health disorders 
[Title/Abstract]) OR (Anxiety [Title/Abstract]) OR (Mood Disorders [Title/Abstract]) OR (Bipolar 
Disorder [Title/Abstract]) OR (Depression [Title/Abstract]) OR  (Schizophrenia [Title/Abstract]) 
OR (Psychosis [Title/Abstract]) OR (Dementia [Title/Abstract]) OR (Cognitive disorders 
[Title/Abstract]) OR (Eating Disorders [Title/Abstract]) OR (Sleep disorders [Title/Abstract]) OR 
(Attention-Deficit Hyperactivity Disorder [Title/Abstract]) AND (Youngsters [Title/Abstract] OR 
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Adolescence [Title/Abstract] OR Young [Title/Abstract])). All studies were initially screened by 
title and abstract to ensure that only the relevant ones were included. Furthermore, a search strategy 
by using specific NPS categories (i.e. synthetic cannabinoids, synthetic cathinones, synthetic 
phenethylamines, etc.) combined with the following terms ‘Adolescence’/ ‘Adolescent’/ ‘Young’/ 
‘Youngsters’/ ‘Mental Health’ was here carried out as well. The above-mentioned search strategies 
were eventually screened with the use of the PubMed filter ‘Adolescent: 13-18 years’. Secondary 
searches were performed using the reference list of included articles and relevant systematic 
reviews. All published articles, without time and/or language restrictions were selected. 
To be included in the present overview, studies had to meet the following criteria: a) being a peer-
reviewed study; b) providing at least an abstract with full results published in English; and c) 
investigating a range of features pertaining to youngsters’ mental health issues associated with 
prior/current NPS intake; d) human studies. As limited level of information was available, non-
systematic and systematic reviews; case-series; and case-reports were here considered as well. 
Studies evaluating only epidemiological data and/or toxicological (i.e. intoxication, fatalities) data 
without considering/reporting data on psychopathological features and/or psychiatric disorders 
and/or mental health amongst youngsters were excluded from the present review.  
After applying the age filter for each search strategy performed, a total of 428 results were identi-
fied (Fig. 1). However, some 317 papers were excluded for a range of reasons, including: 74 papers 
were duplicates; 225 were not consistent with the inclusion criteria and/or with the topic of the re-
search; 9 referred to animal studies; and for 9 papers the full-text was not made available, leaving a 
total of 111 papers to be evaluated. After removal of those 87 papers which did not provide a satis-
factory range of information; and/or which did not specifically focus on youngsters’ mental health; 
we were left with a total of 24 papers to be considered for the present review (see Table 1). To better 
investigate the role of the specific NPS classes and their effects on youngsters’ mental health, the 
literature results were presented as either referring to the whole NPS category or to specific NPS 
classes. However, because of the limited levels of the available literature, the mental health issues 
referring to only two NPS categories, e.g. synthetic cannabinoids and synthetic cathinones were 
here considered. Data extraction was independently carried out by LO and SC; disagreements were 
resolved by discussion and consensus with a third member of the team (DP). Data were collected 
using an ad-hoc developed data extraction spreadsheet. 
 
3. Results 
3.1 Use of NPS; mental health issues; vulnerable sub-populations 
A study by Martinotti et al. [36] compared the prevalence of NPS intake between a population of 
healthy Italian young adults (n=2,615; aged 18-26 years-old) and a psychiatric patient sample 
(n=206). They demonstrated that NPS intake (mainly synthetic cannabinoids) was significantly 
higher amongst the psychotic and bipolar disorder patients. The authors concluded that NPS intake 
may be a likely factor to facilitate the occurrence of a full-blown development of a psychiatric dis-
order; alternatively, psychiatric patients may be more prone to approach NPS compounds because 
these molecules are being perceived as ‘legal’ self-medicating agents [36]. In Japan, a multicentre 
retrospective survey of NPS products’ poisoning events emphasized the involvement of youngsters; 
data were relating to 589 patients from 85 emergency facilities. Indeed, most patients were male 
(89.6%) and young (median age: 30 years; age range: 15-67 years-old). Amongst those hospitalized, 
approximately 5.3% of patients reported psychosis (hallucinations and delusions), 11% anxiety, 
27.3% agitation and irritability; and 1.9% panic attacks [52]. A retrospective review of 388 electron-
ic discharge letters relating to patients released from the Royal Edinburgh Hospital general adult 
psychiatric wards was carried out [53]. NPS were identified in 22.2% of admissions, determining 
psychiatric symptoms in 59.3% of the sample. When compared with non-NPS users (mean age 42.5 
years old), NPS (mostly synthetic cannabinoids) users appeared to be younger (mean age: 36.1), 
males and more likely to present with a forensic history. Furthermore, the diagnosis of drug-induced 
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psychosis was significantly more likely in NPS, vs non NPS, users (p<.001; OR=18.7, 95% CI 8.1 
to 43.0) [53]. A multicentre observational study investigated the prevalence of NPS intake in a 
youngsters’ (aged 18-26 years) Italian psychiatric sample (n=617) [53]. About 8.2% (n=55) of the 
subjects had ingested NPS at least once in their lifetime, whilst 2.2% (n=15) had consumed one, or 
more, NPS over the previous 3 months. Most popular NPS were synthetic cannabinoids (4.5%; 
n=30 subjects), and the three most represented psychiatric diagnoses included bipolar (23.1%; 
n=15), personality (11.8%; n=13), and schizophrenia/psychotic-related disorders (11.6%; n=13) 
[54]. The mental health issues associated with the use of NPS in a sample of 90, mainly <30 years-
old, users admitted to the Ibiza Can Misses Hospital Psychiatric Unit was formally assessed with 
the help of a range of psychometric scales. Most cases were characterized by poly-substance use 
(67%), whilst reporting a previous psychiatric history. Both positive (e.g. delusions and hallucina-
tions) symptoms and hostility/aggression issues were frequent among tetrahydrocannabinol (THC) 
users, whilst anxiety symptoms were more prevalent in the group of sedatives’ users [55]. Finally, a 
survey-based study was carried out to obtain information on the prevalence of ‘drunkorexia’ (e.g. 
self-imposed weight control measures combined with alcohol abuse) combined with drug, including 
NPS, intake in an Italian youngster (aged 18-26) sample (n= 4,275). A significant correlation was 
described between food restriction, binge drinking behaviour, use of cocaine, and NPS use [41]. 
 
3.2 Use of Synthetic Cannabinoids; mental health issues and youngsters 
A large collection of anecdotal reports of mental health issues associated with synthetic canna-
binoids (SC; ‘Spice’) intake was here identified. Many psychiatric symptoms were described; alt-
hough they were typically resembling those of marijuana, they were at times more severe and un-
predictable, including, psychomotor agitation, restlessness, anxiety, tachycardia, mildly elevated 
blood pressure, muscle fasciculation, and hypokalaemia described in a 17-year-old girl after having 
smoked SC [56]. Psychotic symptoms are frequently described, with severe anxiety, paranoia and 
auditory/visual hallucinations [57]. Mood shifts have been described as well; a case-series reviewed 
the records of 11 US individuals aged 15-19 years who were evaluated after having smoked SC 
compounds. All reported feelings of euphoria and memory changes, whilst 9 out of 11 (82%) re-
ported negative mood changes [58]. With the help of a semi-structured interview, a further study 
collected data regarding the use and effects of JWH-018, a synthetic cannabinoid, in 15 patients 
from early twenties to mid-forties (mean age 34) with serious mental illness in a New Zealand fo-
rensic and rehabilitation service [59]. After JWH-018 intake, subjects reported the onset of both 
anxiety and, in 69% of cases, psychotic symptoms [59]. A further case-series described 10 other-
wise US healthy youngsters (range age: 21-25-years-old) admitted with new onset psychosis to the 
psychiatric ward; auditory hallucinations (n=4), visual hallucinations (n=2), paranoid delusions 
(n=9), odd or flat affect (n=6), thought blocking (n=4), disorganized speech (n=6), disorganized be-
haviour (n=7), alogia (n=3), psychomotor retardation (n=6), psychomotor agitation (n=3), and anxi-
ety (n=2) were all identified in these subjects [60]. After having smoked an SC compound, a 17-
year-old male reported to feel dizzy and confused first, and then became combative [61]. A case-
series paper described two cases of adolescents taking SC who developed a new-onset psychosis 
[62], both developing severe agitation, lability of mood, increased  irritability, increased energy, in-
somnia, pressure of speech, disorganized behaviour, flights of ideas, paranoid and grandiose delu-
sions, auditory/visual hallucinations [63]. Interestingly, using psychometric measures psychopatho-
logical symptoms associated with the use of SC and natural cannabis have been compared in a sam-
ple of 367 European users, finding higher scores with SC, indicating a higher likelihood of  sleep 
problems, hypomanic symptoms, and several dimensions the Brief Symptom Inventory (BSI), in-
cluding somatization, obsessive-compulsive behaviours, interpersonal sensitivity, depression, anxie-
ty, hostility, phobic anxiety, paranoid ideation, and psychoticism [64]. 
Many other case-studies reported similar findings [63-69]. Moreover, a longitudinal cohort study 
recruited adolescents (mean age: 16.09 years) from 7 public schools in Texas. Depressive symp-
toms, marijuana use, alcohol use, and SC use at baseline were identified as predictive factors of SC 
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use at 1-year follow-up, whereas anxiety symptoms and impulsivity were not [70]. An observational 
study described 75 adolescents (age range: 12-19-years-old) who had smoked SC; a range of neuro-
psychiatric symptoms was reported in 67% of them [71]. Finally, a paper described the occurrence 
of severe catatonia in two young adolescents who had self-administered with SC [72-73]. 
 
3.3 Use of Synthetic Cathinones; mental health issues and youngsters 
A retrospective paper explored the American Association of Poison Control Centers (AAPCC) da-
tabase to capture all known synthetic cathinone exposures amongst adolescents aged <20 years 
from January 2010 through January 2013 [73]. Similar to previous suggestions [74], the authors re-
ported a total of 1,328 synthetic cathinones’ paediatric exposures; 70.5% of these subjects were 
males, with an average age of 17 years. Psychiatric symptoms users exhibited were psychomotor 
agitation and psychotic symptoms, such as hallucinations and delusions [75]. 
 
4. Discussion and conclusions 
Although the association between NPS and mental health issues in young people is a particularly 
fascinating topic, it has not been yet well explored due to the limited information on NPS; the pecu-
liar features of most NPS [1].; and an always updated virtual exchange of related-information and 
products [2]. Despite the limited levels of information made available so far, to the best of our un-
derstanding we have been able to provide here the first, up-to-date, systematic, review of the use of 
NPS in youngsters and its association with mental health issues.  
The ever-increasing number of NPS emerging worldwide and the parallel changes in drug scenarios 
represent a challenge for psychiatry, and especially so for child and adolescent psychiatry [1, 4, 8, 
12, 14, 21, 34, 36]. Vulnerable subjects, and indeed the technologically literate youngsters, may be 
exposed to a vast range of ‘pro drug’ web pages, which provide direct drug purchasing opportuni-
ties and/or drug information (e.g., description of the drug effects, dose, chemistry and intake experi-
ences) [13-14]. Advanced levels of knowledge relating to NPS are typically provided by drug fo-
ra/blog communities’ members (e.g., the ‘e-psychonauts’ [1, 13]). NPS favourable/unclear legal sta-
tus in many countries has encouraged psychonauts and remaining drug users to supplement their 
habits with these new molecules [12-14]. 
Concerns about NPS impact on mental health arise from the observation that the intake of these 
substances is typically associated with changes of a range of neurotransmitter pathways/receptors 
whose imbalance has been associated with psychopathological conditions. Indeed, the occurrence of 
psychosis has been related (for a comprehensive review, see [1]) to: a) increased central dopamine 
levels, typically described with novel psychedelic phenethylamines, novel stimulants and synthetic  
cathinones; b) significant cannabinoid CB1 receptor activation, achieved with high potency synthet-
ic cannabimimetics; c) 5-HT2A receptor activation, reported with latest generation phenethylamines, 
tryptamine derivatives and hallucinogenic plants; d) antagonist activity at the N-methyl-D-aspartate 
(NMDA) receptors, described with ketamine, methoxetamine (MXE), and their latest derivatives; 
and e) k-opioid receptor activation, typically associated with Salvia divinorum (‘Sally D’) intake. 
One could also argue that, in comparison with adults, the central nervous system of chil-
dren/adolescents may be more vulnerable to the activity of these molecules, hence raising even fur-
ther the levels of mental health concerns [74-76].  
Furthermore, the possibility of interactions among medical treatments and NPS should not be ex-
cluded and this may pose a risk in terms of efficacy of prescribed drugs; symptoms’ worsening; and 
reduced adherence to therapeutic plans [76]. The NPS patterns of abuse; their multiple routes of 
administration; their wide range of potency; and the actual content of the NPS compound(s) ingest-
ed often pose a range of unanswered questions upon admission of youngsters to emergency rooms 
and mental health units [1]. Therefore, treatment decisions are often challenging, and prediction of 
associated potential risks and harms is often not known. In addition, due to the fast‐moving nature 
of the NPS market, there is a limited availability of knowledge on the health implications and harms 
associated with the chronic use of NPS [1; 10]. The inherently complex nature of NPS, with respect 
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to their chemical heterogeneity, sustained emergence of new subcategories, and high prevalence and 
limited available clinical expertise is contributing to significant public health threats [77]. Pharma-
covigilance, and specifically proactive pharmacovigilance activities [76] which monitor and antici-
pate changes in drug abuse, using elements of clinical, epidemiologic, basic science, and social sci-
ence expertise, are needed. Finally, contrasting the recently increasing expansion and availability of 
NPS, the successful example of some countries, where governments responded enacting legislation 
to reduce NPS trade and availability, resulting in a reduction in drug-related psychiatric admissions, 
should be considered [78-79]. Thus, in managing the increasing levels of diffusion of NPS, both 
prevention measures and legislation/drug control policies will need to be promoted and implement-
ed worldwide. 
 
Expert Opinion  
NPS constitute a challenging public health issue. Within the current drug scenario, where ‘tradition-
al’ drugs of abuse are both controlled and easily identified, NPS may be seen as attractive, and es-
pecially so for young people. This is particularly true for synthetic cannabinoids whose external ap-
pearance looks similar to the vastly popular organic cannabis preparations. However, in comparison 
with marijuana/hashish, synthetic cannabinoids are undetectable in standard toxicology tests; signif-
icantly more powerful; lacking in any cannabidiol concentration, which may powerfully modulate 
the dopaminergic THC effects [1]; largely available from the web; and affordable [1, 7]. The evi-
dence here presented, referring to both the European and worldwide NPS scenarios [3-4, 8], empha-
sizes the significant use of synthetic cannabinoids and central nervous system stimulants, such as 
mephedrone/remaining synthetic cathinones, among NPS abusers. Overall, however, poly-substance 
abuse is likely to be the norm in the NPS scenario [4; 34-37; 39-40; 42; 51; 73]. 
Current results may suggest that high levels of NPS use may be identified in people diagnosed with 
psychotic; personality; or bipolar disorders [36, 41, 54-55, 62, 69]. Hence, the co-morbidity of NPS 
use with psychopathological issues should be considered as a public health issue. NPS use, per se, 
may trigger de novo psychopathological issues but can worsen as well already existing mental 
health conditions [1, 52-53, 55-68, 70-72]. One limitation of the studies here identified and de-
scribed, however, is that a clear-cut differentiation between mental illness and psychiatric symptoms 
that can be evoked by NPS use needs to occur. For example, many case series and case reports here 
included mentioned indeed psychiatric symptoms (e.g. anxiety) following NPS/SC use, but no for-
mal mental health disorders. In other words, one could argue that the use of NPS can, in most cases, 
evoke psychiatric symptoms, but not necessarily mental health disorders.  
Planning/implementing a range of prevention activities through information and education, aiming 
at decreasing youngsters’ levels of access to NPS, should be considered. NPS intake and mental 
health issues should be better investigated in longitudinal studies, since virtually nothing is known 
about the long-term consequences of NPS use on the mental and physical health of vulnerable peo-
ple. Furthermore, more studies specifically focused on youngsters (< 20 years-old) should be per-
formed, in order to evaluate the exact correlation between the ingestion of each specific NPS and 
the associated mental health issues. More precisely, we need to better understand and describe in 
detail the role of increased vulnerability for subjects with and without a history of mental disorders. 
In addition, future longitudinal, large sample size, studies should consider the use of clini-
cal/psychopathological data at baseline; their possible modification overtime in association with 
NPS intake whilst eliminating potential confounding factors; and, finally, the neuroimaging corre-
lates of the NPS intake effects on an adolescent subject, who is per definition in his/her growing 
phase of cerebral maturation.  
Clinicians should improve their awareness of drug safety issues, aiming at being better educated in 
recognizing NPS-related toxicity issues, so that potentially life-threatening complications can be 
treated and managed properly. Drug control policies should be improved, and the list of NPS should 
be constantly updated with improvement in detection methods. Given the implication on mental 
health, psychiatric services should adapt to the new drug scenarios, developing innovative engage-
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ment strategies, and building new therapeutic pathways that may improve service integration levels 
[60]. 
In parallel with constant changes in basic scaffolds from which novel molecules can be de-
rived/designed/synthesized, the NPS market will continue to grow. It is likely that increasing levels 
of interest will be given in the near future to the misuse of both prescribing compounds and ‘herbal 
highs’. Overall, this will pose a challenge, since NPS-related toxidromes are, per se, complex and 
unpredictable. Long-term studies, analysing NPS-related consequences, and specifically in young 
subjects, will be encouraged. Consistent and updated drug monitoring practices will be improved. A 
proactive pharmacovigilance approach will monitor and anticipate changes in future drug abuse 
scenario. A combination of prevention activities and control policies will hopefully better deter vul-
nerable populations from accessing NPS compounds. 
 
Article Highlights  
• Over the last decade, a growing number of NPS have been identified. They include a range 
of substances which are being used with recreational purposes. The large availability and 
easy access to NPS through both rogue websites and the ‘deep web’ make them popular 
among vulnerable clients, including young people and those with a history of drug abuse 
and/or mental health issues. Synthetic cannabinoids, central nervous system stimulants (e.g. 
cathinones), phenethylamines, and dissociatives account for most NPS being identified. 
Moreover, NPS may be self-administered in combination with remaining recreational drugs 
such as alcohol, cocaine or opioids. 
• NPS-related clinical toxidromes differ according to the type of NPS ingested and range from 
sympathomimetic effects, euphoria, and agitation to respiratory depression. Fatalities have 
been recorded as well. 
• High levels of NPS use are being identified in people diagnosed with psychotic; personality; 
or bipolar disorders. 
• Unlike remaining recreational drugs, e.g. cocaine and 3,4‐methylenedioxymethamphetamine  
(MDMA; ecstasy), NPS are typically going undetected. Hence, the provision of targeted 
clinical treatments to counteract toxicity and overdose may be problematic.  
• Healthcare professionals, and especially so child and adolescent psychiatrists, should be 
aware of new trends in drug scenarios so that they will be able to better identify possible 
NPS-related psychiatric symptoms. 
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Type of study Setting Substances Outcomes 
Martinotti et al., 
2014 [35] 
206 psychiatric 





Italy NPS • Alcohol consumption is more frequent in the healthy young population vs 
psychiatric young people (79.5% vs 70.7%; p<.003) 
• Cocaine and NPS use is significantly more common amongst psychiatric 
patients (cocaine 8.7% vs 4.6%; p=.002) (NPS 9.8% vs 3%; p<.001) 
Lupi et al., 2017 [40] 4,275 healthy 
subjects (18-26 yy) 
Questionnaire-based 
survey 
Italy Alcohol and NPS • Significant correlation between drunkorexic attitudes and binge drinking 
behaviours (p<.01), use of cocaine (p<.01), and NPS use (p<.01) 
Kamijo et al., 2016 
[51] 
589 patients coming 
from 85 emergency 
facilities 
Multicenter retrospective 
survey of poisoning after 
consumption of products 
containing NPS 
Japan NPS • 89.6% were male and young (median age, 30 years) 
• 88% inhaled NPS contained in herbal products (80.5%) 
• 6.9% reported violence, 4.9% traffic accidents and 1.1% self-injury and/or 
suicidal attempts 
• 17.5% rhabdomyolysis, 12.4% liver injury, 9% acute kidney injury and 
1.9% physical injury 
• synthetic cannabinoids and synthetic cathinones detected only in the 
blood of 5 patients 
Stanley et al., 2016 
[52] 




Cohort study UK (Scottish city) NPS • 22.2% NPS use, contributing to psychiatric symptoms in 59.3% of cases 
• NPS users (vs not-NPS users) are younger (p<.01), male (p<.001) and 
more likely to have a forensic history (p<.001) 
• Drug-induced psychosis significantly higher amongst NPS-users (p<.001; 
OR=18.7) 
• Depression significantly less likely amongst NPS users (p<.005; 
OR=0.133) 
• Cannabis use significantly more likely in NPS users (p<.001; OR=4.2) 
Acciavatti et al., 2017 
[53] 
617 psychiatric 
patients (18-26 yy) 
Multicenter-observational 
study 
Italy (different cities) NPS • 8.2% declared to have used NPS at least once 
• 2.2% had consumed NPS in the previous 3 months 
• Bipolar disorder (23.1%), personality disorder (11.8%) and schizophrenia 
and related disorders (11.6%) were the most frequently associated 
diagnoses 
Martinotti et al., 
2017 [54] 
90 young NPS users 
admitted in the 
Psychiatric Unit     
Questionnaire-based 
survey 
Ibiza All substances, 
including NPS 
• Polydrug abuse was reported by 67.4% of the sample; the sample was 
grouped by the main preferred substance in THC-, stimulants-, and 
depressors-users 
• Most patients reported a previous psychiatric history 
• Positive symptoms resulted to be higher among THC-users (P < .05). 
Anxiety evaluated by SCL-90 was prevalent in the group of Depressors-
users (P < .05). The scores of MOAS and SCL-90 subscale for 







A young adolescent 
(17 yy) 
Case-report USA Synthetic 
cannabinoids 
• Visual hallucinations, restless, anxious 
• Tachycardia, hypertension, diaphoresis, hypokalemia 
Benford and Caplan, 
2011 [56] 
1 adolescent (20 yy) Case-report USA Synthetic 
cannabinoids 
• Anxiety, paranoia, visual and auditory hallucinations 
Castellanos et al 
2011[57] 
11 subjects  
(15-19 yy) 
Case-series USA Synthetic 
cannabinoids 
• Hallucinations, difficulty thinking clearly, confusion, sedation, somno-
lence, disorganization or thought blocking, halting/nonsensical speech, 
alogia, memory changes/problems, amnesia, increased focus, internal un-
rest, agitation, aggression, excitability, restlessness, decreased activity, 
anger, sadness, odd/flat affect, delusion, paranoid thinking, psychomotor 
retardation 
• Tachycardia, hypertension, conjunctival injection, nausea/vomiting, xero-
stomia, tremors, numbness, tingling, lightheadedness, dizziness, seizures, 
pallor, tinnitus, diaphoresis 
Every-Palmer, 2011 
[58] 
15 subjects (early 
twenties to mid-
forties, mean 34 yy) 
with severe mental 
illness 
Exploratory study New Zealand Synthetic 
cannabinoids 
• Pronounced anxiety, florid psychosis with aggression (one subject), other 
psychotic symptoms (not specified) 
 
 
Hurst et al., 2011 
[59] 
10 young adults 
(21-25 yy) 
Case-series USA Synthetic 
cannabinoids 
• Auditory and visual hallucinations, paranoid delusions, odd or flat affect, 
thought blocking, disorganized speech, disorganized behaviour, alogia, 
suicidal ideation, anxiety, distinct waxing and waning stoupourous ap-
pearance, insomnia, psychomotor retardation, psychomotor agitation  
18 
Faircloth et al., 2012 
[60]  
17-year old subject Case-report USA Synthetic 
cannabinoids 
• Confusion, inappropriate response to questions, combative behavior 
• Dizziness, lethargy, emesis, hyperventilation, hypertension, tachycardia, 
tachypnea, hyperglycemia, tremors, hypokalemia, fatigue, pallor, oxygen 
saturation 87% (room air) 
 
 




Case-report Spain Synthetic 
cannabinoids 
• Low mood, insomnia, hyperactivity, anxiety, paranoid delusions, halluci-
nations 
Young et al., 2012 
[62]  
A young adolescent 
(17 yy) 
Case-report USA Synthetic 
cannabinoids 
• Visual hallucinations 
• Lightheadedness particularly with standing, pounding in chest, chest pres-
sure, chest pain, tachycardia followed by significant bradycardia, dyspnea 
on exertion 
Thornton et al., 2012 
[63] 
A young adolescent 
(18 yy) 
Case-report USA Synthetic 
cannabinoids and 
other substances  
• Prolonged psychosis 
Mensen et al., 2019 
[64]  




Europe Natural cannabis 
and synthetic 
cannabinoids 
• Synthetic cannabinoids users were more likely to be associated with   
sleep problems, hypomanic symptoms, and higher scores of several di-
mensions the Brief Symptom Inventory (BSI), including somatization, 
obsessive-compulsive behaviours, interpersonal sensitivity, depression, 
anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism.  
• Natural cannabis use was also highly prevalent in the synthetic canna-
binoids’ user group, while synthetic cannabinoids use was non-prevalent 
in the natural cannabis user group. 
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Harris and Brown, 
2013 [65]  
6 adolescents and 
young adults (17-24 
yy) 
Case series USA Synthetic 
cannabinoids 
• Agitation, hallucinations and somnolence 
• Tachycardia, nausea/vomiting, chest pain syncope, seizure, inability to 
move arms, combativeness, hyper-reflexic 
Brewer and Collins, 
2014 [66] 
Case-studies Review Various Synthetic 
cannabinoids 
• Paranoia, hallucination, psychotic onset, anxiety, psychomotor agitation 
Besli et al., 2015 [67]  16 pediatric patients  Retrospective cohort study Turkey Synthetic 
cannabinoids 
• The most common physical symptoms were eye redness, 
nausea/vomiting, sweating, and altered mental status 
• The most common psychiatric symptoms were agitation, anxiety, 
hallucinations and perceptual changes 
Roberto et al., 2016 
[68] 
1 adolescent (18 yy) Case-report USA Synthetic 
cannabinoids 
• Psychotic episode, insomnia, elated mood, agitation, paranoid ideation, 
thought insertion, thoughts broad-casting, bizarre delusional thoughts, 
disorganized behavior  
Ninnemann et al., 
2017 [69]  
75 adolescents (12-
19 yy) 
Prospective cohort study USA Synthetic 
cannabinoids 
• Depressive symptoms, but not anxiety or impulsivity, together with 
alcohol use and cannabis use predicted to synthetic cannabinoids’ use 
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Observational study USA Synthetic 
cannabinoids 
• 67% of adolescents developed neuropsychiatric symptoms 
Tekulve et al., 2014 
[71] 
1328 adolescents 
(11-20 yy)  
Retrospective cohort study USA Synthetic 
cathinones 
• fever, tachycardia, acidosis, development of seizure, hallucinations and 
delusions  
Khan et al., 2016 [72] Two young 
adolescents (17 and 
21 yy) 
Case-series USA Synthetic 
cathinones 
• catatonia with/without psychotic onset 
 
USA: United States of America; yy: years; N.A.: not applicable. 
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